综上所述,SGLT-2i可通过多种途径使酮体生成增加、清除率下降,导致酮体蓄积而引发酮症酸中毒,由于SGLT-2i可增加尿糖排泄,患者在发生酮症酸中毒时,血糖往往不超过13.9mmoL/L,被称为“血糖不高的DKA”,容易被忽视或漏诊。建议在使用SGLT-2i期间,若患者出现如恶心...
SGLT-2 associated DKA is not an extensively studied phenomenon4. DKA is more common in type 1 diabetes mellitus (T1D) than T2D (50–100 and 4.6–8 episodes per 1000 patients, respectively)5,6. However, it remains a significant cause of morbidity in the T2D population because of an ...
It is possible that SGLT2 inhibitors trigger euglycemic diabetic ketoacidosis in some patients. Possible mechanism of euglycemic DKA induced by SGLT2 inhibitors is illustrated.Wataru OgawaDivision of Diabetes and EndocrinologyKazuhiko SakaguchiDivision of Diabetes and EndocrinologyJournal of Diabetes ...
they are increasingly used in chronic kidney disease (CKD) and heart failure (HF). At the same time, there has been a steady rise in reported cases of diabetic ketoacidosis (DKA) associated with SGLT2is. Diabetic keto...
This narrative review gives an overview of the mechanism of action and differences in the underlying pharmacology of the various SGLT2 inhibitors and discusses the key cardiovascular, heart failure and renal outcomes from completed CVOTs for SGLT2 inhibitors. Discussion highlights important differences in...
【摘要】Sodium glucose co-transporter 2 (SGLT-2) inhibitors have a unique mechanism of action leading to excretion of glucose in the urine and subsequent lowering of plasma glucose. This mechanism is independent of β-cell function; thus, these agents are effective treatment for type 2 diabetes...
Owing to their renal mechanism of action, patients who initiate an SGLT2 inhibitor may experience a decline in eGFR shortly after beginning treatment,44 similar to that observed in some patients after initiating RAS inhibitors.45 An initial decline in eGFR is to be expected and should not be co...
Modest reductions in systolic and diastolic blood pressure have been well recognized in clinical development of SGLT2 inhibitors [9]. While the mechanism of diuresis may lead to immediate antihypertensive effect, other mechanisms like improvement in vascular stiffness may also play a key role. The di...
25 The primary mechanism by which SGLT2 inhibitors are thought to be nephroprotective is through increasing distal sodium delivery and inhibiting tubuloglomerular feedback resulting in afferent vasoconstriction and reduction in intraglomerular pressure.26,27 A marker of this reduction in intraglomerular ...
We also suggest putting in place a mechanism for triggering frequent guidelines updates, if not already present, to ensure that the latest evidence is accounted for. Collaborate on local education initiatives We have acknowledged the lack of awareness that may be a key driver of clinical inertia....